GPT and metabolic dysfunction-associated steatotic liver disease: Among patients with NAFLD (stages 0–3) diagnosed by imaging (ultrasound, CT scan, or MRI) or liver biopsy showing NASH or simple steatosis, and alanine aminotransferase (ALT) > 1.5 upper limit of normal recruited into a phase 3 trial (EVIDENCES II), saroglitazar reduced ALT levels after 16 weeks of therapy [40].